Clinical Trials on Rare Diseases in Hungary

Total 4812 results

R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials

Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 2)

Rheumatoid Arthritis

United States, Germany, Korea, Republic of, Bulgaria, Poland, Taiwan, Mexico, Hungary, Czechia, United Kingdom, Lithuania, Argentina, Brazil, Colombia, Estonia, Latvia, Russian Federation, Romania
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)

Rheumatoid Arthritis

United States, Australia, Austria, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Korea, Republic of, Latvia, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Slovakia, ... and more
Eli Lilly and Company

Completed

A Study in Moderate to Severe Rheumatoid Arthritis (RA-BEAM)

Rheumatoid Arthritis

Argentina, Korea, Republic of, United States, Spain, China, Hungary, Romania, Poland, Belgium, Czechia, France, Japan, Mexico, Russian Federation, United Kingdom, Puerto Rico, Portugal, Greece, Taiwan, Latvia, South Africa, Canada, ... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY)

Rheumatoid Arthritis

Germany, Hungary, Belgium, United States, Argentina, Australia, Austria, Belarus, Brazil, Canada, Chile, Czechia, Estonia, Finland, Greece, Korea, Republic of, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Romania, Russian... and more
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance)

Relapsing Multiple Sclerosis

United States, Mexico, Hungary, China, Germany, Italy, Peru, Poland, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Tunisia, Netherlands, Argentina, Georgia, Hong Kong, Kenya, Dominican Republic, Finland, North Macedonia, Serb...
Janssen-Cilag International NV

Completed

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia

France, Poland, Germany, Spain, Slovenia, Bulgaria, Romania, Israel, Greece, Sweden, Turkey, Czech Republic, Hungary, Lithuania, Latvia, Portugal, Croatia, Slovakia, Austria, United Kingdom, Estonia, Ireland, Denmark, Saudi Arabia
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Russian Federation, Spain, United Kingdom, Austria, Belgium, Mexico, Sweden, Israel, Taiwan, Hungary, Malaysia, Serbia, Turkey, Denmark, Greece, Thailand, North Macedonia, Norway, Portugal, Germany, Romania and more
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-L)

Type 2 Diabetes

United States, Australia, Canada, Chile, Czech Republic, Denmark, Estonia, Hungary, Lithuania, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania
Hoffmann-La Roche
European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical... and other collaborators

Completed

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer (HERA)

Breast Cancer

France, Spain, Switzerland, Greece, Italy, Korea, Republic of, Australia, Canada, Poland, Belgium, United Kingdom, Netherlands, Germany, Chile, Ireland, Portugal, South Africa, Sweden, China, Austria, Hungary, Brazil, Colombia, Thailand, Denma... and more
AstraZeneca
The Gynecologic Oncology Group (GOG) Foundation Inc; The European Network for...

Active, not recruiting

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Endometrial Neoplasms

United States, Belgium, Canada, Germany, Korea, Republic of, Brazil, Hungary, Japan, Poland, Russian Federation, China, Hong Kong, Spain, Israel, Australia, India, Singapore, Greece, Estonia, Lithuania, Mexico, Colombia
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Hoffmann-La Roche

Completed

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom, Australia, Belgium, Brazil, Croatia, France, Canada, Slovakia, Germany, Netherlands, Norway, Italy, Poland, Switzerland, Romania, Bulgaria, Spain, Mexico, Austria, Portugal, Turkey, Sweden, Argentina, Denmark and more
GlaxoSmithKline
PPD

Completed

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Spain, Germany, Hungary, Italy, Philippines, France, United States, Mexico, Brazil, South Africa, Korea, Republic of, Canada, Poland, United Kingdom
Forest Laboratories

Terminated

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Estonia, Hungary, Iceland, Italy, Korea, Republic of, Serbia, Ukraine, Canada, Colombia, Belgium, France, New Zealand, Poland, South Africa, Spain
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)

Coronary Artery Disease | Heart Failure

United States, France, Poland, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Mexico, Portugal, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Japan, Canada, Netherlands, Den... and more
Hoffmann-La Roche

Completed

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
GlaxoSmithKline

Completed

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Neoplasms, Breast

United States, Australia, Canada, Germany, Argentina, Poland, Russian Federation, Belgium, Spain, Latvia, Netherlands, New Zealand, Mexico, Pakistan, Italy, Austria, Chile, Peru, South Africa, Czech Republic, Hungary, Korea, Republic... and more
Hoffmann-La Roche

Completed

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)

Breast Cancer

United States, Korea, Republic of, Canada, United Kingdom, Australia, Belgium, Brazil, France, Slovenia, Spain, Taiwan, Japan, Italy, Argentina, India, Germany, Hungary, Russian Federation, Singapore, Ukraine, Costa Rica, Czechia, G... and more
Eli Lilly and Company

Completed

A Study in Patients With Type 2 Diabetes Mellitus (IMAGINE 2)

Diabetes Mellitus, Type 2

United States, Brazil, Germany, Israel, Italy, United Kingdom, Australia, Hungary, Puerto Rico, Romania, Russian Federation, Spain, Poland, Canada, Greece, Turkey, Mexico, New Zealand, South Africa, Argentina, Finland, Lithuania, Sl...
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3)

Advanced Breast Cancer

Belgium, Italy, Czechia, Hungary, Canada, Netherlands, Germany, Singapore, Australia, Denmark, Poland, Switzerland, Korea, Republic of, Spain, Thailand, Lebanon, Austria, Bulgaria, Russian Federation, Norway, Jordan, United States, ... and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

Multiple Sclerosis

United States, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Moldova, Republic of, Montenegro, North Macedonia and more
Allergan

Completed

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Macular Degeneration

United States, Japan, United Kingdom, Italy, Taiwan, Australia, Canada, Hungary, Poland, Russian Federation, Netherlands, Brazil, Denmark, Peru, South Africa, Turkey
Anthos Therapeutics, Inc.
CYTE Global

Recruiting

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke (GARDENIA)

Atrial Fibrillation

United States, Czechia, Poland, Spain, Germany, Canada, Hungary, United Kingdom, Argentina, Italy, Brazil, Mexico
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (contRAst 2)

Arthritis, Rheumatoid

United States, Australia, Germany, Japan, Korea, Republic of, Poland, Bulgaria, Estonia, Hungary, Mexico, Russian Federation, Spain, Thailand, Colombia, China, Argentina, United Kingdom, France
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
Amgen

Active, not recruiting

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (ROCKET-Ignite)

Atopic Dermatitis

United States, China, Spain, Korea, Republic of, Taiwan, Greece, Slovakia, Germany, Japan, Italy, Hungary, Croatia, Brazil, Poland, Canada, Portugal, Czechia, Argentina, Latvia, Netherlands, Puerto Rico
AbbVie

Active, not recruiting

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Taiwan, United Kingdom
Bayer

Terminated

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (DREAM)

Macular Degeneration

Hong Kong, Korea, Republic of, United States, Canada, Switzerland, Spain, Japan, Italy, Czech Republic, Australia, Austria, Slovakia, Germany, Hungary, Israel, Chile, France, Colombia
Sanofi
Regeneron Pharmaceuticals

Terminated

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (RA-COMPARE)

Rheumatoid Arthritis

United States, Argentina, Australia, Brazil, Chile, Czechia, Finland, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Malaysia, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, F... and more
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)

Non Small Cell Lung Cancer

United States, China, Hungary, Brazil, Argentina, Canada, France, Greece, Italy, Japan, Korea, Republic of, Romania, Spain, Taiwan, Turkey
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (EDITION III)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (FOURIER OLE)

Dyslipidemia

United States, Poland, Czechia, Hungary, Russian Federation, Ukraine, Slovakia
AbbVie

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia Areata

United States, Australia, Japan, Puerto Rico, New Zealand, China, Canada, Brazil, United Kingdom, Argentina, Chile, France, Germany, Hungary, Israel, Korea, Republic of, Poland, Portugal, Spain, Taiwan
Pfizer

Completed

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Metastatic Breast Cancer

Korea, Republic of, Serbia, Argentina, Brazil, Japan, Peru, Turkey, United States, Slovakia, Mexico, Philippines, Poland, Romania, Hungary, India, Portugal, South Africa, Latvia, Thailand, Russian Federation, Ukraine, Chile, Czechia, ...
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (CONCLUDE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Canada, Denmark, Hungary, Serbia, Germany, Greece, Romania, Estonia, Norway
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Odonate Therapeutics, Inc.

Terminated

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)

Breast Cancer

Korea, Republic of, United States, Spain, Canada, Singapore, Taiwan, Australia, Belgium, Thailand, Hungary, Germany, United Kingdom, France, Ukraine, Austria, Czechia, Italy, Poland, Russian Federation
Eli Lilly and Company

Completed

A Study in Second Line Metastatic Colorectal Cancer

Colorectal Cancer

United States, Germany, Italy, Spain, Romania, Taiwan, Belgium, France, Hungary, Japan, Austria, Korea, Republic of, Australia, Sweden, Netherlands, Finland, Argentina, Czechia, Brazil, Greece, India, Israel, Denmark, Portugal, Puerto Rico and more
Hoffmann-La Roche

Completed

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

France, Israel, Italy, Spain, Sweden, Hong Kong, Australia, Canada, Switzerland, United States, Ireland, Denmark, Germany, Taiwan, Russian Federation, China, New Zealand, Austria, United Kingdom, Hungary, Thailand, South Africa, Mexico and more
Hoffmann-La Roche

Completed

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Cardiovascular Disease, Diabetes Mellitus Type 2

Germany, Spain, Korea, Republic of, United States, Colombia, Mexico, Hungary, Canada, Austria, Estonia, Malaysia, Australia, Poland, Thailand, Czech Republic, Latvia, Italy, Romania, Russian Federation, Chile, Lithuania, Sweden, United... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

Systemic Lupus Erythematosus

United States, Australia, Taiwan, Japan, Spain, Singapore, Poland, Greece, Hungary, Mexico, Puerto Rico, Brazil, Argentina, United Kingdom, Chile, Peru, Turkey, Czechia, Portugal, India, Thailand, Bulgaria
Bayer

No longer available

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (CONSIGN)

Colorectal Neoplasms

France, Belgium, Spain, United States, Canada, Switzerland, Germany, Russian Federation, Australia, Austria, Israel, Italy, Mexico, Netherlands, Norway, United Kingdom, Poland, Hungary, Denmark, Portugal, Finland, Sweden, Ireland, Greece and more
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (TEXT)

Breast Cancer

United States, Australia, Switzerland, Italy, Canada, Belgium, Peru, United Kingdom, Egypt, New Zealand, Slovenia, South Africa, Sweden, Hungary, India, Germany, Brazil
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)

Breast Cancer

Belgium, Israel, Spain, Sweden, United States, Switzerland, Russian Federation, Czech Republic, France, Canada, Germany, Korea, Republic of, Australia, Hungary, Thailand, United Kingdom, Italy, Brazil, Slovakia, Poland, India, Norway
Novartis
Bayer

Completed

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Colorectal Neoplasms | Rectal Neoplasms | Colonic Neoplasms

Belgium, Germany, Italy, United States, Taiwan, Switzerland, Spain, Canada, Slovakia, United Kingdom, New Zealand, Australia, Portugal, Brazil, Hungary, Czechia, France, Netherlands, Sweden

Clinical Trials on Rare Diseases in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations